Hepatitis B surface antigen monitoring and management of chronic hepatitis B

Journal of Viral Hepatitis

Volumn 18, Issue 7, 2011, Pages 449-457

  Sonneveld, M J ^a   Zoutendijk, R ^a   Janssen, H L A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

chronic hepatitis B; entecavir; hepatitis B surface antigen; peginterferon; prediction of response; tenofovir

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; CHRONIC HEPATITIS; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; DISEASE CARRIER; DISEASE MARKER; DRUG EFFICACY; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; POST HOC ANALYSIS; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS CONCENTRATION; VIRUS LOAD; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DNA, VIRAL; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; PROGNOSIS;

EID: 79959575261     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01465.x     Document Type: Review

References (68)

1. Dienstag JL,. Hepatitis B virus infection. N Engl J Med 2008; 359: 1486-1500.
2. Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44: 675-684. (Pubitemid 44433724)
3. Thompson AJ, Nguyen T, Iser D, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010; 51: 1933-1944.
4. Janssen HL, Kerhof-Los CJ, Heijtink RA, et al. Measurement of HBsAg to monitor hepatitis B viral replication in patients on alpha-interferon therapy. Antiviral Res 1994; 23: 251-257. (Pubitemid 24122302)
5. Nguyen T, Desmond P, Locarnini S,. The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B. Hepatol Int 2009; 3(Suppl. 1): 5-15.
6. Brunetto MR,. A new role for an old marker, HBsAg. J Hepatol 2010; 52: 475-477.
7. Nguyen T, Thompson AJ, Bowden S, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 2010; 52: 508-513.
8. Jaroszewicz J, Serrano BC, Wursthorn K, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010; 52: 514-522.
9. Sonneveld MJ, Rijckborst V, Senturk H, et al. HBsAg decline during peginterferon alfa-2b therapy for HBeAg-positive chronic hepatitis B depends on HBV genotype: relation to sustained response, Abstract 441. Hepatology 2010; 52.
10. Wursthorn K, Jung M, Riva A, et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 2010; 52: 1611-1620.
11. Sugiyama M, Tanaka Y, Kato T, et al. Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. Hepatology 2006; 44: 915-924. (Pubitemid 46489556)
12. Reijnders JG, Rijckborst V, Sonneveld MJ, et al. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol 2011; 54(3): 449-454.
13. Chan HL, Wong VW, Tse AM, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007; 5: 1462-1468. (Pubitemid 350181604)
14. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750-1758. (Pubitemid 38736340)
15. Chan HL, Wong VW, Wong GL, et al. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology 2010; 52(4): 1232-1241.
16. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73. (Pubitemid 43042691)
17. Fattovich G, Olivari N, Pasino M, et al. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 2008; 57: 84-90.
18. Lok AS, McMahon BJ,. Chronic hepatitis B. Hepatology 2007; 45: 507-539. (Pubitemid 46374607)
19. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
20. Locarnini S,. Molecular virology of hepatitis B virus. Semin Liver Dis 2004; 24 (Suppl. 1): 3-10. (Pubitemid 38738352)
21. Brunetto MR, Oliveri F, Colombatto P, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010; 139: 483-490.
22. Manesis E, Papatheodoridis G, Hadziyannis ES,. Significance of serum HBsAg levels for the definition of the inactive hepatitis B carrier state. Hepatology 2010; 52: Abstract 483.
23. Martinot-Peignoux M, Lada O, Cardoso AF, et al. Quantitative HBsAg: a new specific marker for the diagnosis of HBsAg inactive carriage. Hepatology 2010; 52: Abstract 1397.
24. Kitikumonkun P, Charatcharoenwitthaya P, Chainuvati S, et al. Use of HBsAg level alone or combined with HBV DNA can better separate truly inactive chronic hepatitis B infection from those with subsequent reactivation. Hepatology 2010; 52: Abstract 1415.
25. Li Q, Xie S, Yu J, et al. Factors associated with serum HBsAg levels in chronic hepatitis B virus infection in chinese patients. Hepatology 2010; 52: Abstract 1425.
26. Kim Y, Choi MH, Lee J, et al. The change of quantitative HBsAg level in the natural course of chronic hepatitis B. Hepatology 2010; 52: Abstract 1396.
27. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123-129. (Pubitemid 40091801)
28. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-2695. (Pubitemid 41007823)
29. Wong VW, Wong GL, Yan KK, et al. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 1945-1953.
30. Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008; 135: 459-467.
31. Sonneveld MJ, Rijckborst V, Boucher CA, et al. Prediction of sustained response to peginterferon alfa-2b for Hepatitis B e Antigen-positive chronic hepatitis B using on-treatment Hepatitis B surface Antigen decline. Hepatology 2010; 52: 1251-1257.
32. Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009; 136: 2169-2179.e1-4.
33. Sonneveld MJ, Rijckborst V, Cakaloglu Y, et al. Peginterferon alfa-2b induced HBsAg decline is durable through long-term follow-up in HBeAg-positive patients. Hepatology 2010; 52: Abstract 399.
34. Buster EH, Hansen BE, Lau GK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009; 137: 2002-2009.
35. Flink HJ, van Zonneveld M, Hansen BE, et al. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006; 101: 297-303. (Pubitemid 43381671)
36. Lau G, Marcellin P, Brunetto M, et al. On-treatment monitoring of HBsAg levels to predict response to peginterferon alfa-2 in patients with HBeAg-positive chronic hepatitis B. J Hepatol 2009; 50: S333.
37. Kim B, Kim W, Song E, et al. Serum HBsag levels during peginterferon alfa-2a treatment in HBeAg-positive chronic hepatitis B: a prospective randomised controlled trial. Hepatology 2010; 52: Abstract 390.
38. Phisalprapa P, Charatcharoenwitthaya P, Chainuvati S, et al. On-treatment HBsAg level and HBeAg index can early predict HBeAg seroconversion in chronic hepatitis B, HBeAg-positive patients treated with peginterferon alpha-2a. Hepatology 2010; 52: Abstract 415.
39. Tangkijvanich P, Komolmit P, Mahachai V, et al. Comparison between quantitative hepatitis B surface antigen, hepatitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon-alpha-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B. Hepatol Res 2010; 40(4): 269-277.
40. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-1217. (Pubitemid 39296307)
41. Rijckborst V, Ter Borg MJ, Cakaloglu Y, et al. A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. Am J Gastroenterol 2010; 105: 1762-1769.
42. Rijckborst V, Hansen B, Pinarbasi B, et al. Serum HBsAg levels decrease through long-term follow-up in HBeAg-negative patients achieving a sustained response to peginterferon alfa-2a. Hepatology 2010; 52: Abstract 486.
43. Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 1141-1150.
44. Bonino F, Marcellin P, Lau GK, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56: 699-705. (Pubitemid 46662938)
45. Takkenberg B, zaaijer HL, De Niet A, et al. Baseline HBsAg level and on-treatment HBsAg and HBV DNA decline predict sustained virological response in HBeAg-negative chronic hepatitis B patients treated with peginterferon alfa-2a (Pegasys) and Adefovir (Hepsera); an interim analysis. Hepatology 2009; 50: Abstract 491.
46. Rijckborst V, Hansen BE, Cakaloglu Y, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010; 52: 454-461.
47. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 1151-1157.
48. Marcellin P, Piratvisuth T, Brunetto M, et al. On-treatment decline in serum HBsAg levels predicts sustained immune control 1 year post-treatment and subsequent HBsAg clearance in HBeAg-negative hepatitis B virus-infected patients treated with peginterferon alfa-2a. Hepatol Int 2010; 4: 151.
49. Rijckborst V, Hansen B, Ferenci P, et al. Early on-treatment HBsAg and HBV DNA levels identify HBeAg-negative patients not responding to 48 or 96 weeks of peginterferon alfa-2a therapy. Hepatology 2010; 52: 557A-558A.
50. Moucari R, Martinot-Peignoux M, Mackiewicz V, et al. Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a. Antivir Ther 2009; 14: 1183-1188.
51. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-816. (Pubitemid 36245757)
52. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-2588. (Pubitemid 350294224)
53. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-1020. (Pubitemid 43357805)
54. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-2455.
55. Heathcote EJ, Gane E, De Man R, et al. Long-term (4 years) efficacy and safety of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-positive patients (HBeAg+) with chronic hepatitis B (study 103): preliminary analysis. Hepatology 2010; 52: Abstract 477.
56. Marcellin P, buti M, Krastev Z, et al. Continued efficacy and safety through 4 years of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-negative patients with chronic hepatitis B (study 102): preliminary analysis. Hepatology 2010; 52: Abstract 476.
57. Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 422-430.
58. Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of Tenofovir Disoproxil Fumarate treatment for chronic hepatitis B. Gastroenterology 2011; 140(1): 132-143.
59. Jaroszewicz J, Ho NAH, Deterding K, et al. Prediction of HBsAg loss by quantitative HBsAg kinetics during long-term treatment with nucleo(s)tide analogues. Hepatology 2010; 52: Abstract 395.
60. Zoutendijk R, Hansen B, van Vuuren AJ, et al. Prediction of HBsAg loss using HBsAg decline after long-term virological response to nucleo(s)tide analogue therapy for chronic hepatitis B. Hepatology 2010; 52: 381.
61. Shouval D, Lai CL, Chang TT, et al. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol 2009; 50: 289-295.
62. Reijnders JG, Perquin MJ, Zhang N, et al. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology 2010; 139: 491-498.
63. Cai W, Xie Q, Zhou X, et al. On-treatment serum HBsAg level at 2 years: strong predictor of sustained virologic response to telbivudine for up to 2 years off-treatment in chronic hepatitis B patients. Hepatology 2009; 50: Abstract 424.
64. Bommel F, Bock FJ, Hensel-Wiegel K, et al. Kinetics of HBsAg levels in patients with chronic hepatitis B virus infections during up to 4 years of treatment with acyclic nucleotide analogues. Hepatology 2009; 50: Abstract 458.
65. Moucari R, Bourliere M, Ripault MP, et al. HBsAg decline in chronic hepatitis B patients treated with potent NUCs. Hepatology 2009; 50: Abstract 426.
66. Manesis EK, Hadziyannis ES, Angelopoulou OP, et al. Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 2007; 12: 73-82. (Pubitemid 46340428)
67. Chevaliez S, Hezode C, Grare M, et al. Long-term monitoring of HBsAg kinetics and prediction of HBsAg clearance in patients treated with chronic hepatitis B treated with nucleo(s)tide analogues. Hepatology 2010; 52: Abstract 374.
68. Tjwa ET, van Oord GW, Hegmans JP, et al. Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B. J Hepatol 2011; 54(2): 209-218.